Amgen's lung cancer drug Lumykras will no longer be funded for new patients in England and Wales, following a recommendation from the National Institute for Health and Care Excellence (NICE). The decision is considered a setback for Lumykras, which previously had funding covered by the Cancer Drugs Fund since 2022. The stock dropped 4.24% in after-hours trading to $348.22, following the regulatory update.